Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Investors look for better efficacy from safe cancer immunotherapies

This article was originally published in Scrip

Executive Summary

Company executives and biotech investors are very grateful for the way that Seattle-based Dendreon has paved the way for other cancer vaccines and immunotherapies. While it is still uncertain that the Provenge vaccine for metastatic castrate-resistant prostate cancer and its $93,000 price tag will ever be seen as a significant medical intervention or a commercial success, Dendreon's pioneering journey through both the technical and regulatory space is appreciated widely.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC016634

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel